Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death
- PMID: 15805296
- DOI: 10.1158/0008-5472.CAN-04-2232
Sensitivity of undifferentiated, high-TCR density CD8+ cells to methylene groups appended to tumor antigen determines their differentiation or death
Abstract
CD8(+) cells expressing high numbers of TCR per cell (TCR(hi)) are considered important mediators of antitumor effects. To understand the relationship between TCR density and antigen affinity for TCR in the outcome of stimulation with antigen and differentiation of CTL recognizing tumor antigen, we analyzed perforin induction in ovarian tumor-associated lymphocytes in response to the smallest possible changes in the atomic forces of interaction between antigen and TCR. Stimulating undifferentiated, apoptosis-resistant CD8(+) cells expressing high levels of E75-TCR (TCR(hi)) with variants of the CTL epitope E75, HER-2 (369-377), induced their stepwise differentiation, first to IFN-gamma(+) Perf(-) and to TCR(hi) IFN-gamma(+) Perf(+) cells. Blocking caspase-9 activation at antigen stimulation also enhanced the generation of TCR(hi) Perf(hi) cells, demonstrating that TCR density dictated the pathway of death activated by stimulation with the same agonist. Expansion and differentiation of TCR(hi) Perf(+) CTL required an agonist of optimal CH(2) side chain length, which in this study was equal to two CH(2) groups appended to E75 at the Gly(4) position. Side chains one CH(2) shorter or longer than optimal were either less stimulatory or induced death of TCR(hi) Perf(+) cells. Differentiation of TCR(hi) CD8(+) cells can be finely tuned by synthetic amino acids in the peptide, whose side chains induce small increments in the affinity of the antigen for TCR below the affinity which induce apoptosis.
Similar articles
-
N-terminally LRMK-linked HER-2 peptides, AE-37 [p776(774-788)] and AE-47 [Ava-F7(776-788)], aid differentiation of E75-TCR+CD8+ cells to perforin-positive cells.Anticancer Res. 2009 Jul;29(7):2427-35. Anticancer Res. 2009. PMID: 19596910
-
Stimulation of human T cells by an influenza A vector expressing a CTL epitope from the HER-2/neu protooncogene results in higher numbers of antigen-specific TCRhi cells than stimulation with peptide. Divergent roles of IL-2 and IL-15.Anticancer Res. 2005 Mar-Apr;25(2A):715-24. Anticancer Res. 2005. PMID: 15868901
-
Stimulation of cells from a non-invaded and an invaded lymph node with a HER-2+ tumor with peptides corresponding to T-cell epitopes E75 and G89 induced expansion of central memory cells (TCM) from the metastasis-negative lymph nodes.Int J Oncol. 2004 Jun;24(6):1413-8. Int J Oncol. 2004. PMID: 15138582
-
Antigen-nonspecific activation of CD8+ T lymphocytes by cytokines: relevance to immunity, autoimmunity, and cancer.Arch Immunol Ther Exp (Warsz). 2008 Sep-Oct;56(5):311-23. doi: 10.1007/s00005-008-0033-2. Arch Immunol Ther Exp (Warsz). 2008. PMID: 18836862 Review.
-
Molecular interactions in the activation of effector and precursor cytotoxic T lymphocytes.Immunol Rev. 1995 Aug;146:177-210. doi: 10.1111/j.1600-065x.1995.tb00689.x. Immunol Rev. 1995. PMID: 7493753 Review.
Cited by
-
Final analysis of a phase I/IIa trial of the folate-binding protein-derived E39 peptide vaccine to prevent recurrence in ovarian and endometrial cancer patients.Cancer Med. 2019 Aug;8(10):4678-4687. doi: 10.1002/cam4.2378. Epub 2019 Jul 5. Cancer Med. 2019. PMID: 31274231 Free PMC article. Clinical Trial.
-
Integrity of plasma DNA is inversely correlated with vaccine-induced antitumor immunity in ovarian cancer patients.Cancer Immunol Immunother. 2020 Oct;69(10):2001-2007. doi: 10.1007/s00262-020-02599-4. Epub 2020 May 11. Cancer Immunol Immunother. 2020. PMID: 32393999 Free PMC article.
-
Evaluation of Attenuated Tumor Antigens and the Implications for Peptide-Based Cancer Vaccine Development.J Cancer. 2017 May 11;8(7):1255-1262. doi: 10.7150/jca.16450. eCollection 2017. J Cancer. 2017. PMID: 28607601 Free PMC article.
-
A phase I/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB/IV non-small cell lung cancer.Cancer Immunol Immunother. 2019 May;68(5):799-812. doi: 10.1007/s00262-019-02315-x. Epub 2019 Feb 15. Cancer Immunol Immunother. 2019. PMID: 30770959 Free PMC article. Clinical Trial.
-
Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells.Cancer Immunol Immunother. 2009 Aug;58(8):1185-94. doi: 10.1007/s00262-008-0623-1. Epub 2008 Dec 2. Cancer Immunol Immunother. 2009. PMID: 19048252 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous